Organovo Provides Business Update

Core Insights - Organovo Holdings, Inc. is a clinical stage biotechnology company focused on developing novel treatment approaches for inflammatory bowel disease (IBD) [1] Group 1: Business Update - The company has completed the sale of its FXR Program to Lilly, receiving upfront payments and anticipating future milestone payments [2] - Organovo expects a decrease in expenditures in the coming year due to the elimination of costs associated with the FXR314 program, allowing for a more efficient use of existing capital [2] - The company plans to report its full year financials for the fiscal year ended March 31, 2025, around June 6-10, 2025 [2] Group 2: Research and Development - Organovo utilizes 3D human cellular models of Crohn's disease and ulcerative colitis to evaluate therapeutic opportunities, believing these models increase the likelihood of success in clinical trials [3] - In 2024, FXR314 showed strong performance in improving epithelial barrier function and fibrotic activity in ulcerative colitis models, as presented at the Crohn's and Colitis Congress [3] - FXR314 demonstrated synergistic benefits when paired with an approved Janus kinase (JAK) inhibitor, indicating potential for combination therapies [3] Group 3: Company Overview - Organovo is developing drugs that are effective in 3D human tissues, utilizing proprietary technology to create tissues that mimic native human tissue characteristics [4]